Drug reaction with eosinophilia and systemic symptoms (DRESS) caused by sulfasalazine: a case report and literature review-Reference-Cited by-同舟云学术

Drug reaction with eosinophilia and systemic symptoms (DRESS) caused by sulfasalazine: a case report and literature review

Published:2024-04-22 Issue:2 Volume:18 Page:81-87
ISSN:2310-158X
Container-title:Modern Rheumatology Journal
language:
Short-container-title:Sovremennaâ revmatologiâ

Author:

Fedorov A. S.¹^ORCID,Savelyeva Yu. O.¹^ORCID,Grabovetskay Yu. Yu.¹^ORCID,Rudyuk L. A.²^ORCID,Kuchinskaya E. M.³^ORCID,Kostik M. M.⁴^ORCID

Affiliation:

1. Regional Clinical Hospital of Kaliningrad Region

2. Regional Clinical Hospital of Kaliningrad Region; Immanuel Kant Baltic Federal University

3. V.A. Almazov National Medical Research Center, Ministry of Health of Russia

4. Saint Petersburg State Pediatric Medical University

Abstract

Drug-induced hypersensitivity syndrome (DIHS) or drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare, potentially fatal systemic reaction characterized by multiorgan damage involving the liver, hematopoietic system and skin, and heterogeneous manifestations of fever, rash, lymphadenopathy and eosinophilia with unpredictable course.We describe a 41-year-old female patient who developed DRESS syndrome after taking sulfasalazine prescribed for non-radiographic axial spondyloarthritis. Treatment with intravenous and then oral glucocorticoids was effective. A review of the literature on this topic is presented.

Publisher

IMA Press, LLC

Reference50 articles.

1. Musette P, Janela B. New Insights into Drug Reaction with Eosinophilia and Systemic Symptoms Pathophysiology. Front Med (Lausanne). 2017 Dec 4;4:179. doi: 10.3389/fmed.2017.00179.

2. Ramirez GA, Ripa M, Burastero S, et al. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Focus on the Pathophysiological and Diagnostic Role of Viruses. Microorganisms. 2023 Jan 30;11(2):346. doi: 10.3390/microorganisms11020346.

3. Chen CB, Hung WK, Wang CW, et al. Advances in understanding of the pathogenesis and therapeutic implications of drug reaction with eosinophilia and systemic symptoms: an updated review. Front Med (Lausanne). 2023 Jun 29;10:1187937. doi: 10.3389/fmed.2023.1187937.

4. Rubin L, Talmon A, Ribak Y, et al. Noveltargeted inhibition of the IL-5 axis for drug reaction with eosinophilia and systemic symptoms syndrome. Front Immunol. 2023 Apr 28; 14:1134178. doi: 10.3389/fimmu.2023.1134178.

5. Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol. 2013 Jan;13(1):922. doi: 10.1038/nri3341. Epub 2012 Nov 16.